<a href=GSK” class=”halfleft” src=”https://www.pharmaceutical-technology.com/wp-content/uploads/image-digitalinsightresearch/Archive/nri/pharma/GSK’s%20head%20office.jpg” />

GlaxoSmithKline (GSK) has expanded its respiratory medicines production capacity with the opening of a new £56m manufacturing facility in Ware, UK.

More than £100m was invested in the new facility over the past five years, which has been built to cater to the demand of GSK’s respiratory medicines delivered by Ellipta inhaler.

The Ellipta inhaler is a multi-dose dry powder inhaler (DPI) developed to deliver GSK’s once-daily respiratory medicines.

GSK CEO Sir Andrew Witty said: "This new facility demonstrates our commitment to manufacturing in the UK, which continues to be a very positive environment for life sciences investment.

"We currently export Ellipta inhalers from Ware to more than 74 countries and the new facility opened today will increase capacity to meet growing demand for our new portfolio of respiratory medicines worldwide."

The 4500m² facility is expected to nearly double production of Ellipta inhalers in the region to at least 37 million per year by 2017, of which 95% will be exported.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Life Sciences Minister George Freeman said: "This £56m investment by GSK is fantastic news for Ware and the UK’s thriving life sciences industry.

"This £56m investment by GSK is fantastic news for Ware and the UK’s thriving life sciences industry."

"As well as driving growth and creating 150 new jobs, this expansion of GSK’s medicines manufacturing facility in Ware is a strong endorsement of the UK’s leadership in manufacturing and respiratory medicine."

Since 2013, more than 400 additional roles will have been created at the manufacturing site in Ware, bringing staff numbers to more than 1200, the company said.

In a separate development, GSK has begun a Phase II study to evaluate an anti GM-CSF antibody for inflammatory hand osteoarthritis.

Osteoarthritis causes damage to the surface of joints in the body, leading to joint pain and stiffness.

Image: GSK’s head office in Brentford, London. Photo: courtesy of Ian Wilson.